A

HTA ID Drug Brand Indication Assessment status Date
- Atezolizumab Tecentriq® As monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab. NCPE Assessment Process Complete 25th September 2018
21012 Atezolizumab Tecentriq® As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥50% tumour cells (TC) or ≥10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC. Rapid Review Complete 21st April 2021
22036 Atezolizumab Tecentriq® As an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC. NCPE Assessment Process Complete 15th May 2024
- Atezolizumab Tecentriq® In combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease. NCPE Assessment Process Complete 1st September 2020
19030 Atezolizumab Tecentriq® In combination with carboplatin and etoposide is indicated for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). NCPE Assessment Process Complete 24th September 2020
20060 Atezolizumab in combination with bevacizumab Tecentriq® For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy.   NCPE Assessment Process Complete 5th June 2024
20039 Atezolizumab Tecentriq® Atezolizumab monotherapy is indicated as treatment of locally advanced or metastatic urothelial carcinoma (LaMUC) in adult patients who are considered cisplatin-ineligible and whose tumours have PD-L1 expression ≥5%. Rapid Review Complete 23rd September 2020
21009 Atidarsagene autotemcel Libmeldy® For the treatment of metachromatic leukodystrophy characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity, in children with late infantile or early juvenile forms without clinical manifestations of the disease, and in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline. NCPE Assessment Process Complete 24th January 2024
23059 Atogepant Aquipta® Atogepant is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month. Rapid Review Complete 26th October 2023
23039 Atogepant Aquipta® Prophylaxis of migraine in adults who have at least 4 migraine days per month Rapid Review Complete 21st August 2023
21005 Autologous anti-CD19-transduced CD3+ cells Tecartus® For the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor.   Rapid Review Complete 17th July 2023
22009 Avacopan Tavneos® In combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic  polyangiitis.   NCPE Assessment Process Complete 5th June 2024
- Avanafil Spedra® For the treatment of erectile dysfunction in adult men. Rapid Review Complete 2nd May 2014
20006 Avatrombopag Doptelet® For the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. Rapid Review Complete 2nd April 2020
20058 Avatrombopag Doptelet® For the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Rapid Review Complete 15th February 2021
- Avelumab Bavencio® For the treatment of adults with metastatic Merkel Cell Carcinoma. NCPE Assessment Process Complete 9th October 2018
19046 Avelumab Bavencio® Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. NCPE Assessment Process Complete 23rd June 2021
21001 Avelumab Bavencio® As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed with first line platinum-based induction chemotherapy. NCPE Assessment Process Complete 22nd December 2021
- Axicabtagene Ciloleucel Yescarta® For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. NCPE Assessment Process Complete 25th February 2020
22066 Axicabtagene ciloleucel Yescarta® For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. NCPE Assessment Process complete 16th October 2024
- Axitinib Inlyta® For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine Rapid Review Complete 20th November 2012
- Azelastine hydrochloride and fluticasone propionate (nasal spray) Dymista® For symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient. Rapid Review Complete 28th February 2013
- Azilsartan Edarbi® For the treatment of essential hypertension in adults. Rapid Review Complete 11th January 2012
24037 Aztreonam-avibactam Emblaveo® For the treatment of the following infections in adult patients: • Complicated intra-abdominal infection (cIAI) • Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • Complicated urinary tract infection (cUTI), including pyelonephritis. Aztreonam-avibactam is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. Rapid Review complete 25th October 2024
22070 Oral Azacitidine Onureg® For maintenance treatment in adult patients with acute myeloid leukaemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation. Rapid Review Complete 14th March 2024